Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.

Neukirchen-Strapatsas J, Tuechler H, Porta MD, Fenaux P, Guerci A, Haas R, Rossi M, Sapena R, Sperr WR, Strupp C, Stamatoullas A, Valent P, Germing U, Bennett JM.

Leuk Res. 2019 Feb;77:8-13. doi: 10.1016/j.leukres.2018.12.012. Epub 2018 Dec 28.

PMID:
30605856
2.

Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.

Schuler E, Zadrozny N, Blum S, Schroeder T, Strupp C, Hildebrandt B, Kündgen A, Gattermann N, Aul C, Kondakci M, Kobbe G, Haas R, Germing U.

Ann Hematol. 2018 Dec;97(12):2325-2332. doi: 10.1007/s00277-018-3466-7. Epub 2018 Aug 4.

PMID:
30078145
3.

A human relevance investigation of PPARα-mediated key events in the hepatocarcinogenic mode of action of propaquizafop in rats.

Strupp C, Bomann WH, Spézia F, Gervais F, Forster R, Richert L, Singh P.

Regul Toxicol Pharmacol. 2018 Jun;95:348-361. doi: 10.1016/j.yrtph.2018.04.005. Epub 2018 Apr 5.

PMID:
29626562
4.

Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.

Schuler E, Frank F, Hildebrandt B, Betz B, Strupp C, Rudelius M, Aul C, Schroeder T, Gattermann N, Haas R, Germing U.

Leuk Res. 2018 Feb;65:1-4. doi: 10.1016/j.leukres.2017.12.002. Epub 2017 Dec 5.

PMID:
29216536
5.

An in vitro approach for comparative interspecies metabolism of agrochemicals.

Whalley PM, Bartels M, Bentley KS, Corvaro M, Funk D, Himmelstein MW, Neumann B, Strupp C, Zhang F, Mehta J.

Regul Toxicol Pharmacol. 2017 Aug;88:322-327. doi: 10.1016/j.yrtph.2017.03.020. Epub 2017 Mar 24.

6.

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.

Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N, Bennett JM, Aul C, Germing U.

Leuk Res. 2017 Jun;57:78-84. doi: 10.1016/j.leukres.2017.02.008. Epub 2017 Feb 27.

PMID:
28324772
7.

Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.

Hiwase DK, Singhal D, Strupp C, Chhetri R, Kutyna MM, Wee LA, Harrison PB, Nath SV, Wickham N, Hui CH, Gray JX, Bardy P, Ross DM, Lewis ID, Reynolds J, To LB, Germing U.

Am J Hematol. 2017 Jun;92(6):508-514. doi: 10.1002/ajh.24704. Epub 2017 Mar 20.

8.
9.

Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).

Bennett JM, Tuechler H, Aul C, Strupp C, Germing U.

Leuk Res. 2016 Aug;47:63-9. doi: 10.1016/j.leukres.2016.05.006. Epub 2016 May 12.

PMID:
27258735
10.

Causes of death in 2877 patients with myelodysplastic syndromes.

Nachtkamp K, Stark R, Strupp C, Kündgen A, Giagounidis A, Aul C, Hildebrandt B, Haas R, Gattermann N, Germing U.

Ann Hematol. 2016 May;95(6):937-44. doi: 10.1007/s00277-016-2649-3. Epub 2016 Mar 30.

PMID:
27025507
11.

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Eur J Haematol. 2016 Jul;97(1):33-8. doi: 10.1111/ejh.12679. Epub 2015 Oct 22.

PMID:
26341961
12.

In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.

Lauseker M, Schemenau J, Strupp C, Kündgen A, Gattermann N, Hasford J, Germing U.

Br J Haematol. 2015 Sep;170(5):687-93. doi: 10.1111/bjh.13496. Epub 2015 May 11.

PMID:
25960152
13.

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years.

Neukirchen J, Nachtkamp K, Schemenau J, Aul C, Giagounidis A, Strupp C, Kuendgen A, Kobbe G, Haas R, Germing U.

Leuk Res. 2015 Jul;39(7):679-83. doi: 10.1016/j.leukres.2015.04.001. Epub 2015 Apr 15.

PMID:
25929166
14.

Assessment of an extended dataset of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption.

Aggarwal M, Fisher P, Hüser A, Kluxen FM, Parr-Dobrzanski R, Soufi M, Strupp C, Wiemann C, Billington R.

Regul Toxicol Pharmacol. 2015 Jun;72(1):58-70. doi: 10.1016/j.yrtph.2015.02.017. Epub 2015 Mar 9.

15.

Evaluation of carcinogenic potential of the herbicide glyphosate, drawing on tumor incidence data from fourteen chronic/carcinogenicity rodent studies.

Greim H, Saltmiras D, Mostert V, Strupp C.

Crit Rev Toxicol. 2015 Mar;45(3):185-208. doi: 10.3109/10408444.2014.1003423. Epub 2015 Feb 26. Review.

16.

Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias.

Schuler E, Schroeder M, Neukirchen J, Strupp C, Xicoy B, Kündgen A, Hildebrandt B, Haas R, Gattermann N, Germing U.

Leuk Res. 2014 Dec;38(12):1413-9. doi: 10.1016/j.leukres.2014.09.003. Epub 2014 Sep 17.

PMID:
25444076
17.

Relevance of the 1-year dog study in assessing human health risks for registration of pesticides. An update to include pesticides registered in Japan.

Kobel W, Fegert I, Billington R, Lewis R, Bentley K, Langrand-Lerche C, Botham P, Sato M, Debruyne E, Strupp C, van Ravenzwaay B.

Crit Rev Toxicol. 2014 Nov;44(10):842-8. doi: 10.3109/10408444.2014.936550. Epub 2014 Sep 8. Review.

PMID:
25198386
18.

Assessment of in vitro human dermal absorption studies on pesticides to determine default values, opportunities for read-across and influence of dilution on absorption.

Aggarwal M, Battalora M, Fisher P, Hüser A, Parr-Dobrzanski R, Soufi M, Mostert V, Strupp C, Whalley P, Wiemann C, Billington R.

Regul Toxicol Pharmacol. 2014 Apr;68(3):412-23. doi: 10.1016/j.yrtph.2014.01.012. Epub 2014 Jan 31. Review.

PMID:
24491967
19.

The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.

Zipperer E, Tanha N, Strupp C, Kündgen A, Nachtkamp K, Neukirchen J, Hildebrandt B, Haas R, Gattermann N, Germing U.

Haematologica. 2014 Mar;99(3):e31-2. doi: 10.3324/haematol.2013.101055. Epub 2014 Jan 24. No abstract available.

20.

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.

Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B, Gattermann N, Aul C, Haas R, Germing U.

Leuk Res. 2013 Jan;37(1):64-70. doi: 10.1016/j.leukres.2012.09.021. Epub 2012 Oct 31.

PMID:
23122806
21.

Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.

Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N.

Leuk Res. 2012 Aug;36(8):1067-70. doi: 10.1016/j.leukres.2012.04.006. Epub 2012 May 6.

PMID:
22564985
22.

Relationship of metabolism and cell proliferation to the mode of action of fluensulfone-induced mouse lung tumors: analysis of their human relevance using the IPCS framework.

Strupp C, Banas DA, Cohen SM, Gordon EB, Jaeger M, Weber K.

Toxicol Sci. 2012 Jul;128(1):284-94. doi: 10.1093/toxsci/kfs127. Epub 2012 Apr 5.

23.

Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes.

Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, Starke C, Aul C.

Leuk Res. 2012 Jun;36(6):727-34. doi: 10.1016/j.leukres.2012.02.014. Epub 2012 Mar 13.

PMID:
22421409
24.

Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine.

Brandt O, Mildner M, Egger AE, Groessl M, Rix U, Posch M, Keppler BK, Strupp C, Mueller B, Stingl G.

Nanomedicine. 2012 May;8(4):478-88. doi: 10.1016/j.nano.2011.07.005. Epub 2011 Aug 10.

PMID:
21839058
25.

Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.

Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, Germing U.

Leuk Res. 2011 Dec;35(12):1591-6. doi: 10.1016/j.leukres.2011.06.001. Epub 2011 Jun 25.

PMID:
21708407
26.

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).

Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M.

Haematologica. 2011 Oct;96(10):1433-40. doi: 10.3324/haematol.2011.044602. Epub 2011 Jun 9.

27.

Beryllium metal I. experimental results on acute oral toxicity, local skin and eye effects, and genotoxicity.

Strupp C.

Ann Occup Hyg. 2011 Jan;55(1):30-42. doi: 10.1093/annhyg/meq071. Epub 2010 Dec 31.

28.

Beryllium metal II. a review of the available toxicity data.

Strupp C.

Ann Occup Hyg. 2011 Jan;55(1):43-56. doi: 10.1093/annhyg/meq073. Epub 2010 Dec 31. Review.

29.

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M.

Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.

30.

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, Przychodzen B, Mian SA, Nasser EE, Shooter C, Westwood NB, Strupp C, Gattermann N, Maciejewski JP, Germing U, Mufti GJ.

Blood. 2010 Nov 11;116(19):3923-32. doi: 10.1182/blood-2010-03-274704. Epub 2010 Aug 6.

31.

Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes.

Matsuda A, Germing U, Jinnai I, Araseki K, Kuendgen A, Strupp C, Iwanaga M, Miyazaki Y, Hata T, Bessho M, Gattermann N, Tomonaga M.

Leuk Res. 2010 Aug;34(8):974-80. doi: 10.1016/j.leukres.2009.11.015.

PMID:
20022110
32.

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.

Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, Aul C, Gattermann N, Germing U.

Eur J Haematol. 2009 Nov;83(5):477-82. doi: 10.1111/j.1600-0609.2009.01299.x. Epub 2009 Jun 22.

PMID:
19548919
33.

Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, Strupp C, Gattermann N, Germing U, Mufti GJ.

J Clin Oncol. 2009 Aug 20;27(24):4002-6. doi: 10.1200/JCO.2009.22.6985. Epub 2009 Jun 15.

PMID:
19528370
34.

The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.

Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N, Haas R, Germing U.

Haematologica. 2009 May;94(5):729-32. doi: 10.3324/haematol.2008.002063. Epub 2009 Mar 31.

35.

Impact on survival of different treatments for myelodysplastic syndromes (MDS).

Nachtkamp K, Kündgen A, Strupp C, Giagounidis A, Kobbe G, Gattermann N, Haas R, Germing U.

Leuk Res. 2009 Aug;33(8):1024-8. doi: 10.1016/j.leukres.2008.12.019. Epub 2009 Jan 30.

PMID:
19185917
36.

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M.

J Clin Oncol. 2007 Aug 10;25(23):3503-10.

PMID:
17687155
37.

Chronic myelomonocytic leukemia in the light of the WHO proposals.

Germing U, Strupp C, Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N, Bennett JM.

Haematologica. 2007 Jul;92(7):974-7.

38.

A pilot study of bendamustine in elderly patients with high-risk MDS and AML.

Strupp C, Knipp S, Hartmann J, Gattermann N, Haas R, Germing U.

Leuk Lymphoma. 2007 Jun;48(6):1161-6.

PMID:
17577779
39.

Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome.

Knipp S, Strupp C, Gattermann N, Hildebrandt B, Schapira M, Giagounidis A, Aul C, Haas R, Germing U.

Leuk Res. 2008 Jan;32(1):33-7. Epub 2007 Apr 6.

PMID:
17412418
40.

Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification.

Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A, Strupp C, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Gattermann N, Aul C, Tomonaga M.

Leukemia. 2007 Apr;21(4):678-86. Epub 2007 Feb 1.

PMID:
17268513
41.

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.

Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R.

Haematologica. 2006 Dec;91(12):1596-604.

42.

Myelodysplastic syndromes in patients younger than age 50.

Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, Germing U.

J Clin Oncol. 2006 Dec 1;24(34):5358-65. Epub 2006 Nov 6.

PMID:
17088566
43.

Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.

Germing U, Strupp C, Kuendgen A, Aivado M, Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N.

Br J Haematol. 2006 Jan;132(2):162-7. Erratum in: Br J Haematol. 2006 Jul;134(2):247.

PMID:
16398650
44.

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.

Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N.

Ann Hematol. 2005 Dec;84 Suppl 1:61-6.

PMID:
16270213
45.

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).

Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, Lübbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kündgen A, Mueller T, Haas R, Gattermann N, Aul C.

Leukemia. 2005 Dec;19(12):2223-31.

PMID:
16193087
46.

The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.

Strupp C, Germing U, Aivado M, Kündgen A, Fenk R, Hünerlitürkoglu A, Kobbe G, Haas R, Gattermann N.

Leuk Lymphoma. 2005 Jul;46(7):999-1006.

PMID:
16019550
47.

Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.

Strupp C, Fenk R, Kündgen A, Gattermann N, Haas R, Germing U.

Leuk Res. 2005 Aug;29(8):967-9. Epub 2005 Feb 17.

PMID:
15978949
48.

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.

Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C.

Ann Hematol. 2005 Sep;84(9):569-71. Epub 2005 May 13.

PMID:
15891887
49.

Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.

Fenk R, Hoyer B, Steidl U, Kondakci M, Graef T, Heuk R, Ruf L, Strupp C, Neumann F, Rohr UP, Hildebrandt B, Haas R, Kobbe G.

Leukemia. 2005 Jan;19(1):156-9. No abstract available.

PMID:
15510204
50.

No increase in age-specific incidence of myelodysplastic syndromes.

Germing U, Strupp C, Kündgen A, Bowen D, Aul C, Haas R, Gattermann N.

Haematologica. 2004 Aug;89(8):905-10.

Supplemental Content

Loading ...
Support Center